CN1311810C - 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 - Google Patents
一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 Download PDFInfo
- Publication number
- CN1311810C CN1311810C CNB2004100780974A CN200410078097A CN1311810C CN 1311810 C CN1311810 C CN 1311810C CN B2004100780974 A CNB2004100780974 A CN B2004100780974A CN 200410078097 A CN200410078097 A CN 200410078097A CN 1311810 C CN1311810 C CN 1311810C
- Authority
- CN
- China
- Prior art keywords
- radix
- volatile oil
- water
- solution
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 239000000843 powder Substances 0.000 title claims abstract description 35
- 238000003908 quality control method Methods 0.000 title abstract description 3
- 201000010099 disease Diseases 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000341 volatile oil Substances 0.000 claims abstract description 76
- 238000000605 extraction Methods 0.000 claims abstract description 48
- 238000002360 preparation method Methods 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 39
- 230000001737 promoting effect Effects 0.000 claims abstract description 38
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims abstract description 34
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 27
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 22
- 230000017531 blood circulation Effects 0.000 claims abstract description 22
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims abstract description 17
- 230000004087 circulation Effects 0.000 claims abstract description 17
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 15
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 15
- 208000002193 Pain Diseases 0.000 claims abstract description 15
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 15
- 229960004853 betadex Drugs 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 230000036407 pain Effects 0.000 claims abstract description 15
- 238000001694 spray drying Methods 0.000 claims abstract description 13
- 239000004375 Dextrin Substances 0.000 claims abstract description 7
- 229920001353 Dextrin Polymers 0.000 claims abstract description 7
- 235000019425 dextrin Nutrition 0.000 claims abstract description 7
- 239000000470 constituent Substances 0.000 claims abstract description 6
- 239000006184 cosolvent Substances 0.000 claims abstract description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 4
- 238000005469 granulation Methods 0.000 claims abstract description 4
- 230000003179 granulation Effects 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 107
- 239000008187 granular material Substances 0.000 claims description 62
- 239000000243 solution Substances 0.000 claims description 58
- 238000012360 testing method Methods 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 23
- 238000001256 steam distillation Methods 0.000 claims description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 8
- 238000004821 distillation Methods 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000011260 aqueous acid Substances 0.000 claims description 4
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 230000003544 deproteinization Effects 0.000 claims description 3
- GLYLMXARZJNUEY-UHFFFAOYSA-N dichloromethane;methanol;hydrate Chemical compound O.OC.ClCCl GLYLMXARZJNUEY-UHFFFAOYSA-N 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- HELMCUDQQQWAOG-UHFFFAOYSA-N ethyl acetate;hexane;hydrate Chemical compound O.CCCCCC.CCOC(C)=O HELMCUDQQQWAOG-UHFFFAOYSA-N 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000012850 discrimination method Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims 1
- 235000001785 ferulic acid Nutrition 0.000 abstract description 25
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 24
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 24
- 229940114124 ferulic acid Drugs 0.000 abstract description 24
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 24
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 20
- 206010019233 Headaches Diseases 0.000 abstract description 4
- 206010033557 Palpitations Diseases 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 231100000869 headache Toxicity 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 206010008479 Chest Pain Diseases 0.000 abstract description 3
- 206010047513 Vision blurred Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 206010002368 Anger Diseases 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 240000002045 Guettarda speciosa Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 206010049976 Impatience Diseases 0.000 abstract 1
- 235000006751 Platycodon Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 206010038743 Restlessness Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 229930189914 platycodon Natural products 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000010056 xuefu Substances 0.000 description 23
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 13
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 13
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 13
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 13
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 13
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 13
- 229940025878 hesperidin Drugs 0.000 description 13
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000013558 reference substance Substances 0.000 description 12
- 229960004756 ethanol Drugs 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000019476 oil-water mixture Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- UHNSRFWQBVXBSK-UHFFFAOYSA-N methanol;2,2,2-trifluoroacetic acid Chemical compound OC.OC(=O)C(F)(F)F UHNSRFWQBVXBSK-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
方差来源 | 平方和 | 自由度 | 均方 | F | 显著性 |
萃取剂量加水量提取时间误差 | 8.883.10104.911.48 | 2222 | 4.441.5552.450.74 | 6.012.1071.01 | 不显著不显著显著 |
提取方法 | 挥发油量(g) | 藁本内酯含量(g) |
水蒸汽蒸馏法水蒸汽蒸馏液萃取法改良后提高率(%) | 1.263.54181.0 | 0.1730.656279.2 |
方差来源 | 平方和 | 自由度 | 均方 | F | 显著性 |
β-CD:油包合温度(℃)超声时间(min)误差 | 65.00578.4418.946.20 | 2222 | 32.50289.229.473.10 | 10.4893.263.05 | 不显著显著不显著 |
进风温度(℃) | 出风温度(℃) | 阿魏酸保留率(%) | 含水量(%) | 对制粒的影响 |
190180170 | 908070 | 92.3196.7897.85 | 2.64.15.7 | 稍差非常好较好 |
项目 | 指标成分 | |||
芍药苷 | 藁本内酯 | 阿魏酸 | 橙皮苷 | |
血府逐瘀口服液(mg/支)血府逐瘀颗粒(mg/袋)颗粒比原口服液的提高率(%) | 14.515.35.5 | 0.963.24237.5 | 6.176.454.5 | 16.624.346.39 |
组别 | 剂量(g/kg) | 血小板聚集率(%) | 聚集抑制(%) | ||
1min | 5min | Max | |||
正常组模型组阿斯匹林组血府逐瘀颗粒组血府逐瘀口服液组挥发油组 | --0.22.52.50.012 | 25.1±5.6**33.9±7.026.6±7.8*27.7±4.5*28.5±5.726.8±5.1* | 22.0±14.6***46.2±9.92.0±11.3***30.7±13.4**33.3±12.7*24.0±1 3.7*** | 332±9.4***50.3±8.134.3±8.4***37.6±7.2**∧412±8.8*35.8±7.5** | 31.825.219.528.8 |
组别 | 剂量(g/kg) | 全血粘度(mPa·s) | 血浆粘度(mpa·s) | ||
60s-1 | 5s-1 | 1s-1 | |||
正常组模型组阿斯匹林组血府逐瘀颗粒组血府逐瘀口服液组挥发油组 | 0.22.52.50.012 | 3.62±0.433.90±0.643.38±0.40*3.66±0.243.64±0.333.55±0.34 | 7.56±0.79*8.40±0.70726±0.63**7.40±0.56**△7.80±0.94731±0.68** | 17.71±2.08**20.75±1.7417.5±1.63***18.22±1.64*18.44±2.18*17.96±1.85** | 1.43±0.151.48±0.101.40±0.121.48±0.101.49±0.081.45±0.14 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100780974A CN1311810C (zh) | 2004-09-23 | 2004-09-23 | 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100780974A CN1311810C (zh) | 2004-09-23 | 2004-09-23 | 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1586612A CN1586612A (zh) | 2005-03-02 |
CN1311810C true CN1311810C (zh) | 2007-04-25 |
Family
ID=34604952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100780974A Active CN1311810C (zh) | 2004-09-23 | 2004-09-23 | 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1311810C (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100422737C (zh) * | 2005-09-20 | 2008-10-01 | 天津宏仁堂药业有限公司 | 一种血府逐瘀胶囊的制备方法及其质量标准 |
CN101361839B (zh) * | 2008-05-07 | 2011-05-25 | 吉林敖东延边药业股份有限公司 | 一种血府逐瘀口服液的检测方法 |
CN102302588A (zh) * | 2011-09-20 | 2012-01-04 | 荣成市商贸城卫生所 | 一种治疗心血瘀阻引起心悸的中药组合物 |
CN103055160A (zh) * | 2011-10-19 | 2013-04-24 | 新乡医学院 | 一种治疗血瘀型疼痛中药组合物及其制备方法 |
CN102861157A (zh) * | 2012-10-09 | 2013-01-09 | 张艳春 | 一种治疗气血瘀滞型产后发热的中药合剂 |
CN103356796B (zh) * | 2013-06-24 | 2015-07-22 | 广州中医药大学 | 血府逐瘀颗粒及其制备方法 |
CN103977247A (zh) * | 2014-05-31 | 2014-08-13 | 全椒县尹氏油脂有限公司 | 一种治疗夜梦过多的中药 |
CN110346497A (zh) * | 2019-08-28 | 2019-10-18 | 河南工业大学 | 一种高效液相色谱法检测阿魏酸的方法 |
-
2004
- 2004-09-23 CN CNB2004100780974A patent/CN1311810C/zh active Active
Non-Patent Citations (1)
Title |
---|
中华人民共和国药品标准中药成方制剂第5册 59,中华人民共和国卫生部药典委员会 1992 * |
Also Published As
Publication number | Publication date |
---|---|
CN1586612A (zh) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102416139B (zh) | 一种用于治疗乳腺疾病的中药组合物 | |
CN106324174A (zh) | 一种中药配方颗粒的质量标准 | |
CN103381217B (zh) | 一种六味补血胶囊及其质量控制方法与应用 | |
CN101513519B (zh) | 一种补气养血的中药组合物及其制备方法和质量控制方法 | |
CN1768854B (zh) | 一种用于溃疡性结肠炎的中药胶囊制剂 | |
CN103877244A (zh) | 一种治疗头痛的药物组合物及其制备方法 | |
CN1311810C (zh) | 一种治疗血瘀证的颗粒剂的制备方法及质量控制方法 | |
CN106110143B (zh) | 一种妇科再造制剂的制作工艺 | |
CN102305839A (zh) | 宣肺平喘的中药组合物的检测方法 | |
CN100493579C (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN101293063B (zh) | 治疗更年期综合症的组合物及其制备方法和检测方法 | |
CN103784761A (zh) | 一种治疗眩晕的药物及其制备方法 | |
CN100496555C (zh) | 解毒止痒中药组合物及其制备方法 | |
CN103372073A (zh) | 一种调节血脂的红曲山楂药物组合及其制备方法 | |
CN102000264A (zh) | 治疗更年期综合症的组合物及其制备方法和检测方法 | |
CN102288701A (zh) | 宣肺平喘的中药组合物的检测方法 | |
CN101129974A (zh) | 一种治疗肝病的中药组合物及制备方法 | |
CN103316074B (zh) | 一种花锚提取物、黄芪提取物与甘草提取物的组合药物及其制剂、应用 | |
CN100531721C (zh) | 一种治疗痛经的药物固体制剂及其制备方法 | |
CN101642492B (zh) | 治疗慢性盆腔炎的药物及其制备方法 | |
CN1311809C (zh) | 一种治疗神经衰弱的颗粒剂的制备方法及质量控制方法 | |
CN101229303A (zh) | 一种治疗畏寒型胃炎颗粒剂的制备工艺 | |
CN1970001B (zh) | 一种苦参素、五味子和人参配伍的治疗肝炎的药物组合物 | |
CN101274053B (zh) | 腰息痛胶囊的检测方法 | |
CN1457857A (zh) | 炙甘草颗粒剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NEI MENGGU YITAI PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: YITAI MEDICINE SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., INNER MONGOLIA Effective date: 20080523 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080523 Address after: Ordos the Inner Mongolia Autonomous Region Tianjiao Road Patentee after: Inner Monglia Yicai Pharmaceutical Co., Ltd. Address before: Section 8, Spark Road, Hongshan District, Hongshan District, the Inner Mongolia Autonomous Region, Chifeng Patentee before: Yitai Medicine Science and Technology Development Co., Ltd., Inner Mengolia |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: The Inner Mongolia Autonomous Region City, North Road, Ordos Tianjiao Yitai building Patentee after: Inner Monglia Yicai Pharmaceutical Co., Ltd. Address before: Ordos the Inner Mongolia Autonomous Region Tianjiao Road Patentee before: Inner Monglia Yicai Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: INNER MONGOLIA KANG'ENBEI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: INNER MONGLIA YICAI PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Hangjinqi town the Inner Mongolia Autonomous Region City State Road 109 North 017400 Erdos Patentee after: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Address before: 017000 the Inner Mongolia Autonomous Region Ordos Tianjiao road Yitai building Patentee before: Inner Monglia Yicai Pharmaceutical Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20050302 Assignee: Zhejiang Conba Pharmaceutical Co., Ltd. Assignor: Inner Mongolia Kang'enbei Pharmaceutical Co., Ltd. Contract record no.: 2017150000009 Denomination of invention: Process for preparing granular powder for treating blood stasis disease and quality control method Granted publication date: 20070425 License type: Common License Record date: 20171127 |
|
EE01 | Entry into force of recordation of patent licensing contract |